English | 中文
UserName:
Password: 
 
Vital Therapies, Inc. (VTI) is developing the first human liver cell-based Extracorporeal Liver Assist Devic (ELAD.).  ELAD provides metabolic support for patients with severe liver failure by processing toxins and synthesizing proteins that are key products of normal human liver function.  The WHO identified the worldwide market for acute-on-chronic liver failure at approximately 12 million patients. In China alone there are over 400,000 deaths each year from liver disease.  VTI has completed a successful pivotal trial and filed for market approval in China ...
Intro>> Memory
43information in total 20/Page this1/3Page     Page